Futuximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Futuximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target HER1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C6468H10002N1724O2055S46
Molar mass 146.3 kDa

Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It acts as an immunomodulator and also binds to HER1.[2]

This drug was developed by Symphogen.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).